IBRANCE® (palbociclib)| RWE in Older Patients with mBC | PfizerPro Ireland

This site is intended only for healthcare professionals resident in the Republic of Ireland

Log out

Our medicines

Therapy areas

Explore content

Materials

Videos

Podcasts

Let’s connect

Let's connect

Clinical efficacy & safety

PALOMA-2

Trial design overview

Patient baseline characteristics

Progression-free survival (primary endpoint)

Overall survival (secondary endpoint)

Tumour control (secondary endpoint)

PALOMA-2 summary

PALOMA-3

Trial design overview

Patient baseline characteristics

Progression-free survival (primary endpoint)

Overall survival (secondary endpoint)

Tumour control (secondary endpoint)

Safety

Safety overview

Pooled laboratory abnormalities

PALOMA-2 AEs

PALOMA-3 AEs

Selected safety features

IBRANCE long-term safety

GI and liver toxicities

Effect of IBRANCE on QTc interval

Elderly patients

Visceral disease patients

Dose reduction effect on efficacy

RW evidence

Value of RWE

What is real-world evidence?

What is the value of RWE?

P-REALITY and P-REALITY X

P-REALITY Overview

P-REALITY OS and rwPFS

P-REALITY X Overview

P-REALITY X OS and rwPFS

IRIS

IRIS Overview

IRIS PFS and OS

POLARIS

POLARIS Overview

POLARIS Patient-Reported Outcomes

MADELINE

MADELINE Overview

MADELINE Patient Characteristics

MADELINE Patient-Reported Outcomes

PalomAGE

PalomAGE Overview

RWE in Older Patients with mBC

P-VERIFY

P-VERIFY Study

Patient-reported outcomes

PALOMA-2: FACT-B scores

PALOMA-3: EORTC QLQ-C30 scores

PALOMA-3: Time to deterioration in pain symptoms

Dosing

Recommended dosing schedule

Recommended dose modifications for AEs

Monitoring

One scheduled monitoring provision

Prescribing Information

Resources

Materials

RWE in older patients with mBC

A challenge when treating older patients is the lack of evidence to inform delivery of cancer care due to their under-representation in clinical trials. RWE may provide valuable information to supplement available data on efficacy and safety of treatment in this heterogeneous patient group.¹

In real-world studies, older patients with HR+/HER2- mBC derived clinical benefit from IBRANCE combined with ET treatment compared with ET alone.^2-4

FLATIRON Database real-world PFS and OS in older patients²

When analyzed by age group, median rwPFS and median OS remained longer in patients who received IBRANCE in combination with letrozole versus letrozole alone in both the 65–74 and the ≥75-years-old age groups.²

PalomAGE Cohort B: QoL in women aged ≥70⁵

In women with resistant and/or pre-treated mBC, global QoL was maintained at 6 months.⁵

Following 6 months of IBRANCE treatment, a clinically meaningful reduction in pain scores was observed (≥10 points). No clinically meaningful changes occurred in other domains and scales.⁵

PaloMAGE toxicities^6,7

The toxicity profile for older patients treated with IBRANCE was consistent with that seen in clinical trials.^6,7 No new safety signals were detected.⁶

Observational retrospective analyses are designed to evaluate associations among variables and cannot establish causality. Observational retrospective analyses are not intended for direct comparison with clinical trials.

Explore More

IBRANCE dosing

Explore more

CI = confidence interval; ET = endocrine therapy; HR = hazard ratio; HR+/HER2- = hormone receptor-positive, human epidermal growth factor receptor 2-negative; LET = letrozole; mBC = metastatic breast cancer; MedDRA = Medical Dictionary for Regulatory Activities; NE = not estimable; OS = overall survival; PFS = progression-free survival; QoL = quality of life; RWE = real-world evidence; rwPFS = real-world progression-free survival; sIPTW = stabilized inverse probability of treatment weighting.

References:

Habr D, et al. J Natl Cancer Inst. 2021;113:1460-1464.

Rugo HS, et al. ESMO 2021. Poster 236P.

Clifton K, et al. Breast Cancer Res Treat. 2019;175:667-674.

El Badri S, et al. Breast. 2021;60:199-205.

Brain E, et al. SABCS 2021. Poster P1-18-04.

Caillet P, et al. Oral presentation at ASCO 2021.

Rugo HS, et al. Eur J Cancer. 2018;101:123-133.

PalomAGE

IBRANCE Summary of Product Characteristics

Product Characteristics

Legal Category: S1A
Further information is available upon request

PP-IBR-IRL-0649. August 2023

Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)

Adverse events should also be reported to Pfizer Medical Information on 1800 633 363

PfizerPro Account

Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.

Account

Log out

This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie

This website is brought to you by Pfizer Healthcare Ireland Unlimited Company, The Watermarque Building, Ringsend Road, Dublin 4, Dublin, Ireland, D04 K7N3. Registered in the Republic of Ireland No. 127002. Directors: D. Mangone (Managing), O. Gavan, D. Kennedy. Company Secretary: M.Byrne.

PP-UNP-IRL-0832. October 2024

You are now leaving PfizerPro

You are now leaving PfizerPro Ireland. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer. Pfizer accepts no responsibility for the content or services of the linked site.

PP-UNP-IRL-0832. October 2024